Here at Last: Treatment Options for VEXASNovember 15, 2023We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for…View Resource New Biomarkers and Therapeutics Show Potential in Still's DiseaseNovember 14, 2023Adult-onset Still’s disease (AOSD) is a rare complex, sporadic, systemic autoinflammatory disease similar to…View Resource Anakinra Effective in Systemic JIA, Irrespective of HLA-DRB1 and IL1RN VariantsNovember 6, 2023A prospective study of first line use anakinra in systemic juvenile idiopathic arthritis (sJIA) proved…View Resource Sleep Apnea Smart Watches (10.13.2023)October 13, 2023Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past…View Resource FDA Approves Canakinumab for Gout FlaresAugust 30, 2023The US Food and Drug Administration (FDA) has approved canakinumab (Ilaris) for the treatment of gout flares in…View Resource Mono- and Oligo- are Different (8.18.2023)August 18, 2023Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.…View Resource EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation SyndromeJuly 26, 2023A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance, and…View Resource ICYMI: LAVLI – A New Autoinflammatory DisorderJuly 6, 2023Editor’s note: This article originally appeared March 28, 2023, and is being shared again…View Resource EULAR 2023 Notes from Milan (6.09.2023)June 9, 2023Dr. Jack Cush reviews highlight abstracts and sessions – covering lupus, RA, gout, Still’s…View Resource AOSD: Young vs. Elderly OnsetJune 1, 2023Adult onset still’s disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and…View Resource 12345…678910
New Biomarkers and Therapeutics Show Potential in Still's DiseaseNovember 14, 2023Adult-onset Still’s disease (AOSD) is a rare complex, sporadic, systemic autoinflammatory disease similar to…View Resource Anakinra Effective in Systemic JIA, Irrespective of HLA-DRB1 and IL1RN VariantsNovember 6, 2023A prospective study of first line use anakinra in systemic juvenile idiopathic arthritis (sJIA) proved…View Resource Sleep Apnea Smart Watches (10.13.2023)October 13, 2023Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past…View Resource FDA Approves Canakinumab for Gout FlaresAugust 30, 2023The US Food and Drug Administration (FDA) has approved canakinumab (Ilaris) for the treatment of gout flares in…View Resource Mono- and Oligo- are Different (8.18.2023)August 18, 2023Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.…View Resource EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation SyndromeJuly 26, 2023A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance, and…View Resource ICYMI: LAVLI – A New Autoinflammatory DisorderJuly 6, 2023Editor’s note: This article originally appeared March 28, 2023, and is being shared again…View Resource EULAR 2023 Notes from Milan (6.09.2023)June 9, 2023Dr. Jack Cush reviews highlight abstracts and sessions – covering lupus, RA, gout, Still’s…View Resource AOSD: Young vs. Elderly OnsetJune 1, 2023Adult onset still’s disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and…View Resource 12345…678910
Anakinra Effective in Systemic JIA, Irrespective of HLA-DRB1 and IL1RN VariantsNovember 6, 2023A prospective study of first line use anakinra in systemic juvenile idiopathic arthritis (sJIA) proved…View Resource Sleep Apnea Smart Watches (10.13.2023)October 13, 2023Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past…View Resource FDA Approves Canakinumab for Gout FlaresAugust 30, 2023The US Food and Drug Administration (FDA) has approved canakinumab (Ilaris) for the treatment of gout flares in…View Resource Mono- and Oligo- are Different (8.18.2023)August 18, 2023Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.…View Resource EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation SyndromeJuly 26, 2023A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance, and…View Resource ICYMI: LAVLI – A New Autoinflammatory DisorderJuly 6, 2023Editor’s note: This article originally appeared March 28, 2023, and is being shared again…View Resource EULAR 2023 Notes from Milan (6.09.2023)June 9, 2023Dr. Jack Cush reviews highlight abstracts and sessions – covering lupus, RA, gout, Still’s…View Resource AOSD: Young vs. Elderly OnsetJune 1, 2023Adult onset still’s disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and…View Resource 12345…678910
Sleep Apnea Smart Watches (10.13.2023)October 13, 2023Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past…View Resource FDA Approves Canakinumab for Gout FlaresAugust 30, 2023The US Food and Drug Administration (FDA) has approved canakinumab (Ilaris) for the treatment of gout flares in…View Resource Mono- and Oligo- are Different (8.18.2023)August 18, 2023Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.…View Resource EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation SyndromeJuly 26, 2023A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance, and…View Resource ICYMI: LAVLI – A New Autoinflammatory DisorderJuly 6, 2023Editor’s note: This article originally appeared March 28, 2023, and is being shared again…View Resource EULAR 2023 Notes from Milan (6.09.2023)June 9, 2023Dr. Jack Cush reviews highlight abstracts and sessions – covering lupus, RA, gout, Still’s…View Resource AOSD: Young vs. Elderly OnsetJune 1, 2023Adult onset still’s disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and…View Resource 12345…678910
FDA Approves Canakinumab for Gout FlaresAugust 30, 2023The US Food and Drug Administration (FDA) has approved canakinumab (Ilaris) for the treatment of gout flares in…View Resource Mono- and Oligo- are Different (8.18.2023)August 18, 2023Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.…View Resource EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation SyndromeJuly 26, 2023A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance, and…View Resource ICYMI: LAVLI – A New Autoinflammatory DisorderJuly 6, 2023Editor’s note: This article originally appeared March 28, 2023, and is being shared again…View Resource EULAR 2023 Notes from Milan (6.09.2023)June 9, 2023Dr. Jack Cush reviews highlight abstracts and sessions – covering lupus, RA, gout, Still’s…View Resource AOSD: Young vs. Elderly OnsetJune 1, 2023Adult onset still’s disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and…View Resource 12345…678910
Mono- and Oligo- are Different (8.18.2023)August 18, 2023Dr. Jack Cush reviews the news and journal reports from RheumNow.com this past week.…View Resource EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation SyndromeJuly 26, 2023A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance, and…View Resource ICYMI: LAVLI – A New Autoinflammatory DisorderJuly 6, 2023Editor’s note: This article originally appeared March 28, 2023, and is being shared again…View Resource EULAR 2023 Notes from Milan (6.09.2023)June 9, 2023Dr. Jack Cush reviews highlight abstracts and sessions – covering lupus, RA, gout, Still’s…View Resource AOSD: Young vs. Elderly OnsetJune 1, 2023Adult onset still’s disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and…View Resource 12345…678910
EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation SyndromeJuly 26, 2023A EULAR/American College of Rheumatology task force has established evidence based, up-to-date guidance, and…View Resource ICYMI: LAVLI – A New Autoinflammatory DisorderJuly 6, 2023Editor’s note: This article originally appeared March 28, 2023, and is being shared again…View Resource EULAR 2023 Notes from Milan (6.09.2023)June 9, 2023Dr. Jack Cush reviews highlight abstracts and sessions – covering lupus, RA, gout, Still’s…View Resource AOSD: Young vs. Elderly OnsetJune 1, 2023Adult onset still’s disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and…View Resource 12345…678910
ICYMI: LAVLI – A New Autoinflammatory DisorderJuly 6, 2023Editor’s note: This article originally appeared March 28, 2023, and is being shared again…View Resource EULAR 2023 Notes from Milan (6.09.2023)June 9, 2023Dr. Jack Cush reviews highlight abstracts and sessions – covering lupus, RA, gout, Still’s…View Resource AOSD: Young vs. Elderly OnsetJune 1, 2023Adult onset still’s disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and…View Resource 12345…678910
EULAR 2023 Notes from Milan (6.09.2023)June 9, 2023Dr. Jack Cush reviews highlight abstracts and sessions – covering lupus, RA, gout, Still’s…View Resource AOSD: Young vs. Elderly OnsetJune 1, 2023Adult onset still’s disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and…View Resource 12345…678910
AOSD: Young vs. Elderly OnsetJune 1, 2023Adult onset still’s disease (AOSD) is an autoinflammatory condition characterized by fevers, arthritis, and…View Resource